Figure 7.
Proposed model for targeting VCX2 in tumors. VCX2 is rarely expressed in tumors, but can be epigenetically activated by treatment with DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors. Enhanced production of VCX2 will make tumor cells susceptible to anti-VCX2 T-cell responses or to T-cell therapy with T cells genetically modified to express VCX2-specific T-cell receptors.
